WallStSmart

Novartis AG ADR (NVS)vsSeaboard Corporation (SEB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 476% more annual revenue ($56.58B vs $9.83B). NVS leads profitability with a 23.9% profit margin vs 5.9%. SEB appears more attractively valued with a PEG of 0.65. SEB earns a higher WallStSmart Score of 65/100 (B-).

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 3.3Quality: 5.5
Piotroski: 4/9Altman Z: 1.96

SEB

Strong Buy

65

out of 100

Grade: B-

Growth: 5.3Profit: 4.5Value: 9.3Quality: 8.0
Piotroski: 5/9Altman Z: 3.59
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-51.8%)

Margin of Safety

-51.8%

Fair Value

$110.12

Current Price

$146.03

$35.91 premium

UndervaluedFair: $110.12Overvalued
SEBUndervalued (+49.9%)

Margin of Safety

+49.9%

Fair Value

$11112.70

Current Price

$4540.14

$6572.56 discount

UndervaluedFair: $11112.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$277.42B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

SEB5 strengths · Avg: 9.6/10
P/E RatioValuation
7.5x10/10

Attractively priced relative to earnings

Price/BookValuation
0.8x10/10

Reasonable price relative to book value

EPS GrowthGrowth
277.0%10/10

Earnings expanding 277.0% YoY

Altman Z-ScoreHealth
3.5910/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.658/10

Growing faster than its price suggests

Areas to Watch

NVS4 concerns · Avg: 2.5/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

PEG RatioValuation
2.592/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

SEB4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.6%4/10

3.6% revenue growth

Profit MarginProfitability
5.9%3/10

5.9% margin — thin

Operating MarginProfitability
4.0%3/10

Operating margin of 4.0%

Free Cash FlowQuality
$-150.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : SEB

The strongest argument for SEB centers on P/E Ratio, Price/Book, EPS Growth. PEG of 0.65 suggests the stock is reasonably priced for its growth.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.

Bear Case : SEB

The primary concerns for SEB are Revenue Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

NVS profiles as a declining stock while SEB is a value play — different risk/reward profiles.

NVS carries more volatility with a beta of 0.49 — expect wider price swings.

SEB is growing revenue faster at 3.6% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

SEB scores higher overall (65/100 vs 51/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Seaboard Corporation

INDUSTRIALS · CONGLOMERATES · USA

Seaboard Corporation is a global agribusiness and transportation company. The company is headquartered in Merriam, Kansas.

Visit Website →

Want to dig deeper into these stocks?